Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community Pharmacy Services | 4 | 2020 | 24 | 1.440 |
Why?
|
| Pharmacists | 5 | 2020 | 56 | 1.300 |
Why?
|
| Cyclonic Storms | 3 | 2018 | 75 | 1.140 |
Why?
|
| Puerto Rico | 15 | 2024 | 1376 | 1.020 |
Why?
|
| Platelet Aggregation Inhibitors | 7 | 2024 | 77 | 0.970 |
Why?
|
| Acute Coronary Syndrome | 3 | 2024 | 43 | 0.790 |
Why?
|
| Patient Care | 2 | 2019 | 31 | 0.750 |
Why?
|
| Disaster Planning | 2 | 2018 | 58 | 0.650 |
Why?
|
| Education, Pharmacy | 1 | 2019 | 56 | 0.570 |
Why?
|
| Thrombosis | 1 | 2018 | 81 | 0.560 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 242 | 0.490 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 959 | 0.440 |
Why?
|
| Motivation | 1 | 2018 | 492 | 0.440 |
Why?
|
| Dietary Supplements | 1 | 2016 | 208 | 0.440 |
Why?
|
| Opioid-Related Disorders | 3 | 2021 | 188 | 0.420 |
Why?
|
| Health Services Accessibility | 3 | 2024 | 680 | 0.360 |
Why?
|
| Smoking | 1 | 2018 | 1019 | 0.360 |
Why?
|
| Buprenorphine | 2 | 2021 | 51 | 0.340 |
Why?
|
| Humans | 23 | 2025 | 42163 | 0.340 |
Why?
|
| Aryldialkylphosphatase | 3 | 2018 | 14 | 0.330 |
Why?
|
| Pharmacogenetics | 4 | 2024 | 63 | 0.300 |
Why?
|
| Ticlopidine | 2 | 2018 | 17 | 0.280 |
Why?
|
| Male | 11 | 2024 | 22779 | 0.260 |
Why?
|
| Vaccination | 2 | 2021 | 332 | 0.260 |
Why?
|
| Blood Platelets | 2 | 2018 | 80 | 0.260 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 3077 | 0.260 |
Why?
|
| Aged | 7 | 2024 | 7982 | 0.250 |
Why?
|
| Genotype | 4 | 2024 | 796 | 0.230 |
Why?
|
| Female | 11 | 2024 | 24018 | 0.220 |
Why?
|
| Middle Aged | 7 | 2024 | 11819 | 0.220 |
Why?
|
| Narcotic Antagonists | 2 | 2021 | 78 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 860 | 0.210 |
Why?
|
| Algorithms | 2 | 2024 | 508 | 0.210 |
Why?
|
| Benzodiazepines | 1 | 2023 | 19 | 0.210 |
Why?
|
| Drug Storage | 2 | 2020 | 28 | 0.180 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 32 | 0.180 |
Why?
|
| Gene Frequency | 2 | 2018 | 203 | 0.180 |
Why?
|
| Adult | 5 | 2021 | 13458 | 0.170 |
Why?
|
| Mental Disorders | 1 | 2025 | 377 | 0.170 |
Why?
|
| Guaifenesin | 1 | 2020 | 1 | 0.170 |
Why?
|
| Dextromethorphan | 1 | 2020 | 3 | 0.170 |
Why?
|
| Intention | 1 | 2021 | 103 | 0.170 |
Why?
|
| Dexamethasone | 1 | 2020 | 55 | 0.160 |
Why?
|
| Drug Compounding | 1 | 2020 | 90 | 0.160 |
Why?
|
| Clinical Competence | 1 | 2020 | 154 | 0.150 |
Why?
|
| Professional Competence | 1 | 2019 | 42 | 0.150 |
Why?
|
| Caribbean Region | 3 | 2025 | 75 | 0.150 |
Why?
|
| Galactosyltransferases | 1 | 2018 | 6 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 36 | 0.150 |
Why?
|
| Platelet Aggregation | 1 | 2018 | 21 | 0.150 |
Why?
|
| Community-Institutional Relations | 1 | 2020 | 208 | 0.150 |
Why?
|
| Stents | 1 | 2018 | 66 | 0.150 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2018 | 57 | 0.140 |
Why?
|
| Telecommunications | 1 | 2018 | 1 | 0.140 |
Why?
|
| Electric Power Supplies | 1 | 2018 | 15 | 0.140 |
Why?
|
| Tetrazoles | 1 | 2018 | 45 | 0.140 |
Why?
|
| Perception | 1 | 2019 | 209 | 0.140 |
Why?
|
| Professional Role | 1 | 2018 | 40 | 0.140 |
Why?
|
| Prescription Drugs | 1 | 2018 | 32 | 0.140 |
Why?
|
| Pharmacies | 1 | 2018 | 23 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 222 | 0.130 |
Why?
|
| Drug Resistance | 1 | 2017 | 97 | 0.130 |
Why?
|
| Disasters | 1 | 2018 | 74 | 0.130 |
Why?
|
| Food Supply | 1 | 2018 | 120 | 0.130 |
Why?
|
| Certification | 1 | 2016 | 21 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 415 | 0.120 |
Why?
|
| Papillomavirus Vaccines | 1 | 2017 | 168 | 0.110 |
Why?
|
| Health Education | 1 | 2017 | 358 | 0.110 |
Why?
|
| Young Adult | 3 | 2019 | 4936 | 0.100 |
Why?
|
| Neoplasms | 1 | 2023 | 1341 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 729 | 0.080 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 245 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2024 | 845 | 0.070 |
Why?
|
| Platelet Function Tests | 2 | 2018 | 7 | 0.070 |
Why?
|
| Latin America | 1 | 2025 | 53 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2020 | 1574 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2020 | 1586 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2024 | 55 | 0.050 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2024 | 52 | 0.050 |
Why?
|
| Genomics | 1 | 2025 | 289 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 421 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2025 | 429 | 0.050 |
Why?
|
| Naloxone | 1 | 2021 | 56 | 0.050 |
Why?
|
| West Indies | 1 | 2021 | 13 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 727 | 0.040 |
Why?
|
| Dinucleoside Phosphates | 1 | 2020 | 11 | 0.040 |
Why?
|
| Expectorants | 1 | 2020 | 1 | 0.040 |
Why?
|
| Leadership | 1 | 2021 | 84 | 0.040 |
Why?
|
| Antitussive Agents | 1 | 2020 | 7 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 61 | 0.040 |
Why?
|
| Viscosity | 1 | 2020 | 46 | 0.040 |
Why?
|
| Color | 1 | 2020 | 38 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 92 | 0.040 |
Why?
|
| Drug Stability | 1 | 2020 | 127 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 256 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 385 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 471 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 249 | 0.040 |
Why?
|
| Neonatal Screening | 1 | 2018 | 24 | 0.040 |
Why?
|
| Psychometrics | 1 | 2020 | 350 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2018 | 146 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 233 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2018 | 189 | 0.030 |
Why?
|
| Educational Status | 1 | 2019 | 335 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 236 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 268 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 311 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 438 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1139 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 587 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 638 | 0.030 |
Why?
|
| Parents | 1 | 2019 | 359 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 1848 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 733 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 960 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 1516 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1001 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 1221 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 2803 | 0.020 |
Why?
|
| United States | 1 | 2020 | 5072 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 3942 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 5950 | 0.020 |
Why?
|